• Japan Lifeline posted Q1 net sales of JPY 15.9 billion, up 8.8% year over year, while operating profit fell 9.4% to JPY 3 billion.
• Net income attributable to owners of the parent edged up 0.3% to JPY 2.31 billion, with basic EPS at JPY 32.93.
• Growth was led by EP/Ablation sales rising 12.5% to JPY 8.19 billion, while Cardiac Rhythm Management slipped 4.7% to JPY 3.23 billion.
• Operating profit declined as SG&A expenses rose 12.9% to JPY 6.21 billion on higher R&D and personnel costs.
• Japan Lifeline kept its FY ending March 2027 forecast unchanged, targeting net sales of JPY 63.2 billion and net income attributable to owners of the parent of JPY 8 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JLL - Japan Lifeline Co. Ltd. published the original content used to generate this news brief on July 30, 2026, and is solely responsible for the information contained therein.